DRIO - ラボスタイル・イノベ―ションズ (DarioHealth Corp.) ラボスタイル・イノベ―ションズ



symbol DRIO
会社名 LabStyle Innovations Corp (ラボスタイル・イノベ―ションズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 ダリオ・ヘルス(DarioHealth Corp)(旧名:Labstyle Innovations Corp)はデジタル・ヘルス会社である。同社は、顧客にスマートフォンなどのモバイル機器を用する実験室テスト機能を有する技術の開発・商業化に従事する。同社の製品Dario Smart Diabetes Management Solution(Dario)は、ポケット・サイズ、血糖監視装置及びダリオスマートメーターと連合するソフトウェア・アプリケーションをベースするモバイル、リアルタイム、クラウドベース、糖尿病管理ソリューションである。   ラボスタイル・イノベ―ションズはイスラエルのデジタル・ヘルス・アプリ企業。モバイルで健康状態を検査するアプリの開発・商業化に従事する。糖尿病のためのアプリ「Dario」は、ランセット装置に特有の使い捨てテストカ―トリッジを利用、スマ―トフォンなどで血糖値を測定することが可能。血糖値の自己モニタリングとクラウドベ―スのサ―ビスを結合する。   DarioHealth Corp. is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, the Company empowers individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Its cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario™mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease.
本社所在地 9 Halamish Street Caesarea Industrial Park 3088900 ISR
代表者氏名 Yoav Shaked Yoav Shaked
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +972 3-622-2929
設立年月日 40756
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 21人
url http://mydario.com
nasdaq_url https://www.nasdaq.com/symbol/drio
EBITDA EBITDA(百万ドル) -14.50800
終値(lastsale) 0.93
時価総額(marketcap) 19847679.63
時価総額 時価総額(百万ドル) 19.84768
売上高 売上高(百万ドル) 6.76800
企業価値(EV) 企業価値(EV)(百万ドル) 14.65468
当期純利益 当期純利益(百万ドル) -24.40300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 DarioHealth Corp revenues increased 72% to $3.8M. Net loss applicable to common stockholders increased from $845K to $9.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Revaluation of warrants decrease of 100% to $1K (income) General and administrative increase of 22% to $3.8M (expense).



   DarioHealth Chosen by Regional Primary Care Provider PeopleOne Health as its Digital Behavioral Health Partner  2021/08/31 11:00:00 PR Newswire
NEW YORK, Aug. 31, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it has been selected by regional primary care provider PeopleOne Health to be the digital behavioral health solution of choice for
   DarioHealth Corp. (DRIO) CEO Erez Raphael on Q2 2021 Results - Earnings Call Transcript  2021/08/16 18:32:04 Seeking Alpha
   Why Is DarioHealth Falling After Earnings?  2021/08/16 15:02:43 Benzinga
DarioHealth Corp (NASDAQ: DRIO ) reported second-quarter FY21 revenue growth of 194% year-on-year to $5.26 million, beating the analyst consensus of $5.11 million. The non-GAAP billings rose 186% Y/Y to $5.13 million from higher sales and the consolidation of Upright revenues. Margin: The gross margin contracted 690 bps to 28.7% Full story available on Benzinga.com
   DarioHealth EPS misses by $0.13, beats on revenue  2021/08/16 10:52:39 Seeking Alpha
   DarioHealth Reports Strong Second Quarter 2021 Results and Operational Highlights  2021/08/16 10:40:00 Business Insider Markets
NEW YORK, Aug. 16, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the second quarter of 2021 and provided a corporate and commercial update.
   DarioHealth touts data for diabetes management platform  2021/07/01 18:55:32 Drug Delivery Business
DarioHealth (NSDQ:DRIO) recently presented data supporting its artificial intelligence (AI)-powered diabetes management platform. New York-based Darios research examined users who were given access to a new product experience designed to drive better health habits and behaviors through its AI-driven personalization engine. According to a news release, results presented at the American Diabetes Association (ADA) 81st [] The post DarioHealth touts data for diabetes management platform appeared first on Drug Delivery Business .
   Digital Therapeutics Market Therapeutic Survey Reviews, Analysis 2021 |VOLUNTIS, Digital Therapeutics, Inc., Dariohealth Corp, BioBeats  2021/06/18 12:16:41 OpenPR
The report studies the Global Digital Therapeutics Market with many aspects of the industry like the market size, market status, market trends, and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key
   DarioHealth Expands Footprint in Musculoskeletal Sensor Technologies with the Upright GO S  2021/06/16 12:30:00 Benzinga
NEW YORK , June 16, 2021 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO ), a leader in the global digital therapeutics (DTx) market, announced today the launch of the Upright GO S, a new wearable sensor based on the company''s pioneering biofeedback technologies to make better back health accessible to more people. This new product from Upright, by Dario, is part of the company''s planned growth strategy for increasing platform membership across both business partnerships and consumer channels. Currently, Dario has more than 185,000 members across its integrated suite of digital therapeutics for chronic and mental health needs. "One of the strengths of Upright''s sensor-based solutions is the successful track record of consumer adoption. The Upright GO S continues that legacy by offering a more affordable option to make digital health solutions accessible to a larger number of people in support of our mission and membership growth strategy," said Erez Raphael , CEO of DarioHealth. New research published in the journal Demography documents the growing prevalence of chronic back and neck pain in U.S. adults, with the greatest increase in pain affecting those in lower socioeconomic classes. 1 Employers are also paying attention, as back pain becomes a significant problem for their populations, especially for employees who spend significant amounts of time sitting.
   DarioHealth to be a part of Russell 2000 and 3000 Indexes  2021/06/15 13:05:38 Seeking Alpha
   DarioHealth to be Added to Russell 2000® and 3000® Indexes  2021/06/15 12:30:00 PR Newswire
NEW YORK, June 15, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell U.S. Indexes annual
   DarioHealth Announces Closing of wayForward Acquisition  2021/06/08 00:00:00 BioSpace
DarioHealth Corp., a pioneer in the global digital therapeutics market, announced the consummation of the previously announced acquisition of PsyInnovations, Inc. through the merger of PsyInnovations into DarioHealth''s wholly-owned subsidiary, WF Merger Sub, Inc., which changed its name to PsyInnovations, Inc.
   DarioHealth Corp Shares Close the Week 26.2% Higher - Weekly Wrap  2021/06/04 22:30:00 Kwhen Finance
DarioHealth Corp (DRIO) shares closed this week 26.2% higher than it did at the end of last week. The stock is currently up 43.7% year-to-date, up 260.2% over the past 12 months, and down 79.5% over the past five years. This week, the Dow Jones Industrial Average rose 0.3%, and the S&P 500 rose 0.5%. Trading Activity Shares traded as high as $22.20 and as low as $16.51 this week.Shares closed 3e+1% below its 52-week high and 3e+2% above its 52-week low.Trading volume this week was 9.3% higher than the 10-day average and 32.6% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 50.5% The company's stock price performance over the past 12 months beats the peer average by 808.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   DarioHealth Releases Study Demonstrating the Impact of Personalized Digital Interventions to Improve Self-Management of Diabetes  2021/06/04 00:00:00 BioSpace
DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, announced today it will be presenting results of a new study at the 14th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2021; June 2-5, 2021).
   DarioHealth to Participate in the Stifel 2021 Virtual Cross Sector Insight Conference  2021/06/03 00:00:00 BioSpace
DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today that the company plans to participate in the upcoming Stifel 2021 Virtual Cross Sector Insight Conference.
   DarioHealth touts research on digital therapeutics for diabetes patients  2021/05/27 14:23:03 Drug Delivery Business
DarioHealth (NSDQ:DRIO) announced today that recently published research supports its digital therapeutic platform for type 2 diabetes. New York-based DarioHealth published a new study through a letter to the editor in the Journal of Diabetes Science and Technology, according to a news release. The study observed participants using DarioHealths digital therapeutics for diabetes management, monitoring for [] The post DarioHealth touts research on digital therapeutics for diabetes patients appeared first on Drug Delivery Business .

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 ラボスタイル・イノベ―ションズ DRIO DarioHealth Corp.)


 twitter  (公式ツイッターやCEOツイッターなど)